Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 23, 2018 - Issue 3
Submit an article Journal homepage
779
Views
5
CrossRef citations to date
0
Altmetric
Review

Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors

Alessia SpagnuoloDivision of Medical Oncology, ‘S. G. Moscati’ Hospital, Avellino, ItalyView further author information
,
Paolo MaioneDivision of Medical Oncology, ‘S. G. Moscati’ Hospital, Avellino, ItalyView further author information
&
Cesare GridelliDivision of Medical Oncology, ‘S. G. Moscati’ Hospital, Avellino, ItalyCorrespondence[email protected]
View further author information
Pages 231-241 | Received 12 Jun 2018, Accepted 20 Sep 2018, Published online: 15 Oct 2018

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Akito Fukuda & Tatsuya Yoshida. (2023) Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure. Expert Review of Anticancer Therapy 23:11, pages 1157-1167.
Read now
Dehua Zhao, Jing Chen, Mingming Chu, Xiaoqing Long & Jisheng Wang. (2020) Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. Drug Design, Development and Therapy 14, pages 1663-1681.
Read now
Yi-Min Liu, Chun-Nan Kuo & Jing-Ping Liou. (2020) Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). Expert Opinion on Therapeutic Patents 30:5, pages 351-373.
Read now
G. Hamilton & M.J. Hochmair. (2019) An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Expert Opinion on Pharmacotherapy 20:13, pages 1551-1561.
Read now
Junyi Yang & Weiliang Gong. (2019) Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Expert Review of Clinical Pharmacology 12:3, pages 173-178.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.